Frazier Life Sciences Public Fund, L.P. 13D and 13G filings for Trevi Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 11:21 am Purchase | 2024-12-31 | 13G | Trevi Therapeutics, Inc. TRVI | Frazier Life Sciences Public Fund, L.P. | 10,664,774 11.900% | 3,283,684 (+44.49%) | Filing |
| 2024-11-06 10:30 am Purchase | 2024-09-30 | 13G | Trevi Therapeutics, Inc. TRVI | Frazier Life Sciences Public Fund, L.P. | 7,381,090 10.200% | 717,500 (+10.77%) | Filing |
| 2022-10-07 2:51 pm Purchase | 2022-10-05 | 13G | Trevi Therapeutics, Inc. TRVI | Frazier Life Sciences Public Fund, L.P. | 6,663,590 11.400% | 2,847,131 (+74.60%) | Filing |
| 2022-04-18 1:32 pm Purchase | 2022-04-11 | 13G | Trevi Therapeutics, Inc. TRVI | Frazier Life Sciences Public Fund, L.P. | 3,816,459 10.000% | 3,816,459 (New Position) | Filing |